Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Poststroke patients: implications for the cardiologist

K. Fox*

Royal Brompton Hospital, London, U.K.

* Kim Fox, Royal Bromptom & National Heart and Lung Hospital, Department of Cardiology, Sydney Street, London SW3 6NP, U.K.

Abstract

PROGRESS (Perindopril pROtection aGainst REcurrent Stroke Study) was the first trial specifically designed to determine the effects of blood pressure lowering on stroke and cardiac events among patients with a history of cerebrovascular disease, regardless of age, sex, ethnicity, concomitant therapy or blood pressure. A total of 6105 individuals with previous stroke or transient ischaemic attack were randomly assigned to receive active treatment with the angiotensin-converting enzyme inhibitor perindopril (4 mg/day), with the addition of the diuretic indapamide at the discretion of treating physicians. After 4 years of follow-up, perindopril-based therapy not only reduced the risk for stroke by 28% () but also reduced the risk for total coronary events by 21% (), including a 38% reduction in non-fatal myocardial infarction, and the risk for congestive heart failure by 26% (). Both stroke and ischaemic heart disease make huge contributions to the overall global burden of disease, and so these positive results should have major implications for cardiovogists. In addition, heart failure is more common in patients with vascular disease, and represents a further and increasing public health problem in industrialized countries with ageing populations. Finally, the management of patients with previous stroke and normal blood pressure remained an unmet medical need in clinical medicine. PROGRESS has demonstrated that a perindopril-based regimen is of clinical importance for preventing stroke and cardiac events in both hypertensive and non-hypertensive patients with stroke or transient ischaemic attack.

Key Words: Blood pressure • Heart failure • Indapamide • Myocardial infarction • Perindopril • Stroke

References

  1. Murray CJL, Lopez AD. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 Projected to 2020. Cambridge, MA: Harvard School of Public Health; 1996.
  2. Michaud CM, Murray CJL, Bloom BR. Burden of disease: implications for future research. JAMA. 2001;285:535–539[Abstract/Free Full Text]
  3. Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet. 2001;357:1612–1616[CrossRef][Web of Science][Medline]
  4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60–69[Abstract/Free Full Text]
  5. Rich MW. Heart failure disease management: a critical review. J Card Fail. 1999;5:64–75[Web of Science][Medline]
  6. Lloyd-Jones DM. The risk of congestive heart failure: sobering lessions from the Framingham Heart Study. Curr Cardiol Rep. 2001;3:184–190[Medline]
  7. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–391[Free Full Text]
  8. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774[CrossRef][Web of Science][Medline]
  9. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA. 1983;250:2942–2946[Abstract/Free Full Text]
  10. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol. 2000;53:229–235[CrossRef][Web of Science][Medline]
  11. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562[Abstract/Free Full Text]
  12. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22:228–236[Abstract/Free Full Text]
  13. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283–291[Abstract/Free Full Text]
  14. Caro JJ, Huybrechts KF, Duchesne IStroke Economic Analysis Group. Management patterns and costs of acute ischemic stroke: an international study. Stroke. 2000;31:582–590[Abstract/Free Full Text]
  15. Eisenstein EL, Shaw LK, Anstrom KJ, et al. Assessing the clinical and economic burden of coronary artery disease: 1986–1998. Med Care. 2001;39:824–835[CrossRef][Web of Science][Medline]
  16. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354:1457–1463[CrossRef][Web of Science][Medline]
  17. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81:1110–1115[CrossRef][Web of Science][Medline]
  18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041[CrossRef][Web of Science][Medline]
  19. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens. 1996;14(suppl 2):S41–S46[Web of Science]
  20. PROGRESS Management Committee. PROGRESS — Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens. 1999;17:1647–1655[Web of Science][Medline]
  21. Neal B, Chapman N, Chalmers J, et alPROGRESS Collaborative Group. Cardiac outcomes in the Perindopril Protection Against Recurrent Stroke Study. [abstract P0708]J Hypertens. 2002;20(suppl 4):S169 on behalf of the
  22. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular diseases. Eur Heart J. 2003;24:475–484[Abstract/Free Full Text]
  23. Di Pasquale G, Pozzati A. Heart disease and stroke. Fieschi C, Fisher M. Prevention of Ischemic Stroke. London, UK: Martin Dunitz Ltd; 1999. p. 27–50
  24. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke. 1992;23:1250–1256[Abstract/Free Full Text]
  25. Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis. 2002;12:171–180[Web of Science]
  26. Love BB, Grover-McKay M, Biller J, Rezai K, McKay CR. Coronary artery disease and cardiac events with asymptomatic and symptomatic cerebrovascular disease. Stroke. 1992;23:939–945[Abstract/Free Full Text]
  27. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:1255–1256[Web of Science][Medline]
  28. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796–800[Abstract/Free Full Text]
  29. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000;31:2080–2086[Abstract/Free Full Text]
  30. Qureshi AI, Suri FK, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621–1628[Abstract/Free Full Text]
  31. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CDA. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke. 2000;31:469–475[Abstract/Free Full Text]
  32. Kernan WN, Horwitz RI, Brass LM, Viscoli CM, Taylor KJ. A prognostic system for transient ischemia or minor stroke. Ann Intern Med. 1991;114:552–557
  33. Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke. 2000;31:456–462[Abstract/Free Full Text]
  34. Lai SM, Alter M, Friday G, Sobel E. Prognosis for survival after an initial stroke. Stroke. 1995;26:2011–2015[Abstract/Free Full Text]
  35. Heyden S, Heiss G, Heyman A, et al. Cardiovascular mortality in transient ischemic attacks. Stroke. 1980;11:252–255[Abstract/Free Full Text]
  36. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol. 2002;1:149–156[CrossRef][Web of Science][Medline]
  37. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246–253[Abstract/Free Full Text]
  38. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:316–320[CrossRef][Web of Science][Medline]
  39. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002;39:634–638[Abstract/Free Full Text]
  40. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol. 2002;39:219–224[Abstract/Free Full Text]
  41. Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J. 1998;19:J52–J55 suppl J

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?